Clinical Research Directory
Browse clinical research sites, groups, and studies.
Feeding Tolerance and Growth of Preterm Infants Consuming a Supplement Containing Two Human Milk Oligosaccharides (HMOs)
Sponsor: Société des Produits Nestlé (SPN)
Summary
The goal of this post-market study is to describe the effect of a liquid supplement containing 2 specific human milk oligosaccharides (HMOs), 2'-fucosyllactose \[2'FL\] and lacto-N-neotetraose \[LNnT\], on feeding tolerance, growth, and adverse events of special interest in preterm infants in a real-world setting. A comparison with data collected retrospectively from a historical group at each site will be made for time to reach full enteral feeding, growth and adverse events. Infants in the historical group were not exposed to an HMO supplement but followed the same local nutrition protocol to avoid confounding by differences in clinical or feeding practice.
Official title: Feeding Tolerance and Growth of Preterm Infants Consuming a Supplement Containing Two Human Milk Oligosaccharides (HMOs): A Post-Market Study
Key Details
Gender
All
Age Range
0 Days - 14 Days
Study Type
INTERVENTIONAL
Enrollment
188
Start Date
2023-11-20
Completion Date
2026-02-28
Last Updated
2025-12-08
Healthy Volunteers
No
Conditions
Interventions
HMO supplement
Liquid supplement containing 2 specific HMOs. Supplement will be given 3-4 times a day, not mixed with any feeding.
Locations (6)
Kepler Universitätsklinikum Linz
Linz, Austria
Evangelisches Waldkrankenhaus Spandau
Berlin-Spandau, Germany
Kinderklinik Darmstadt
Darmstadt, Germany
Wilhelmstift Hamburg
Hamburg, Germany
Uniklinik Heidelberg
Heidelberg, Germany
Klinikum Nürnberg
Nuremberg, Germany